title: Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness.
abstract: OBJECTIVE
  The effectiveness of antiretroviral treatment (ART) was compared in 416 naive patients from a French clinical cohort infected with B and non-B HIV-1 subtypes.
  
  
  METHODS
  Time to HIV viral load (VL) undetectability was calculated for each subtype group. Three other parameters were estimated 3, 6 and 12 months after enrolment: clinical progression (that is, AIDS-defining events or death), changes in CD4 cell counts from baseline and proportion of patients achieving an undetectable VL (<400 HIV-RNA copies/ml).
  
  
  RESULTS
  In this cohort, 317 patients (76%) were infected with a B subtype and 99 (24%) with a non-B subtype. Median time to VL undetectability was similar in the B subtype group [147 days, 95% confidence interval (CI) 119-165] and non-B subtype group (168 days, 95% CI: 105-234; P=0.16). After adjusting for AIDS-defining events at enrolment, baseline CD4 cell counts and VL, and for the treatment on which patients were initiated, no association was found between HIV subtypes and time to VL undetectability (B subtype vs non-B subtype: hazard ratio=0.80, 95% CI: 0.62-1.02, P=0.07). In the 3, 6 and 12 months after enrolment, subtype had no impact on clinical progression, CD4 cell count or VL responses to ART. This suggests that B and non-B subtypes do not affect first-line therapy efficacy, which is encouraging in view of the worldwide spread of non-B HIV-1 subtypes and the increasing availability of ART in developing countries. However, in this study we did not take into account individual non-B subtype species, therefore further studies should be designed to evaluate the efficacy of these regimens in patients with particular non-B subtypes.
authors.affiliation: Virology Department, Centre Hospitalier Universitaire de Lille, France. l-bocket@chru-lille.fr
authors.forename: Laurence
authors.initials: L
authors.lastname: Bocket
authors.forename: Antoine
authors.initials: A
authors.lastname: Cheret
authors.forename: Sylvie
authors.initials: S
authors.lastname: Deuffic-Burban
authors.forename: Philippe
authors.initials: P
authors.lastname: Choisy
authors.forename: Yann
authors.initials: Y
authors.lastname: Gerard
authors.forename: Xavier
authors.initials: X
authors.lastname: de la Tribonnière
authors.forename: Nathalie
authors.initials: N
authors.lastname: Viget
authors.forename: Faïzo
authors.initials: F
authors.lastname: Ajana
authors.forename: Anne
authors.initials: A
authors.lastname: Goffard
authors.forename: Francis
authors.initials: F
authors.lastname: Barin
authors.forename: Yves
authors.initials: Y
authors.lastname: Mouton
authors.forename: Yazdan
authors.initials: Y
authors.lastname: Yazdanpanah
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D015331:Cohort Studies; D005260:Female; D005602:France; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D013045:Species Specificity; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents